Published in:
Open Access
01-12-2016 | Review
Elotuzumab for the treatment of multiple myeloma
Authors:
Yucai Wang, Larysa Sanchez, David S. Siegel, Michael L. Wang
Published in:
Journal of Hematology & Oncology
|
Issue 1/2016
Login to get access
Abstract
Elotuzumab is one of the first two monoclonal antibodies that gained FDA approval for the treatment of multiple myeloma (MM). It targets SLAMF7, which is highly expressed in normal plasma and MM cells as well as natural killer (NK) cells. Elotuzumab demonstrated significant anti-myeloma activity in preclinical studies, and its mechanisms of action include mediating antibody-dependent cell-mediated cytotoxicity, enhancing cytotoxicity of NK cells, and inhibiting MM cell interaction with bone marrow stromal cells. In clinical trials, elotuzumab in combination with immunomodulatory drugs and proteasome inhibitors has demonstrated an excellent efficacy and safety profile in treating MM.